Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.

@article{Ott2017PembrolizumabIP,
  title={Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.},
  author={Patrick A. Ott and Elena {\'E}lez and Sandrine Hiret and Dong-Wan Kim and Anne Morosky and Sanatan Saraf and Bilal Piperdi and Janice M Mehnert},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2017},
  volume={35 34},
  pages={
          3823-3829
        }
}
  • P. OttE. Élez J. Mehnert
  • Published 16 August 2017
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Purpose The safety and efficacy of pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), were assessed in patients with programmed death ligand 1 (PD-L1)-expressing extensive-stage small-cell lung cancer (SCLC) in the multicohort, phase Ib open-label KEYNOTE-028 study ( ClinicalTrials.gov identifier: NCT02054806). Methods Patients with SCLC received pembrolizumab 10 mg/kg every 2 weeks for 24 months or until disease progression or intolerable toxicity occurred. PD-L1… 

Figures and Tables from this paper

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.

  • H. ChungS. Piha-Paul P. Ott
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2019

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer

In a recent clinical trial that included patients with previously untreated ES-SCLC, pembrolizumab in combination with platinum/etoposide met its progression-free survival endpoint, but overall survival did not cross the threshold for superiority.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive‐Stage Small Cell Lung Cancer (SCLC)

  • S. GadgeelN. Pennell G. Kalemkerian
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2018

Complete response to pembrolizumab in a patient with extensive-stage small-cell lung cancer: a case report.

An 86-year-old female patient with extensive-stage disease (ED-SCLC) who was treated with pembrolizumab after relapse following first-line therapy and achieved a complete response (CR) in only one month after initiation of treatment is reported.

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

  • Stephen V. LiuM. Reck L. Horn
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2021
Adding atezolizumab to CP/ET as 1L treatment for ES-SCLC continued to demonstrate improved OS and a tolerable safety profile at the updated analysis, confirming the regimen as a new standard of care.

Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study

It is hypothesized that poly (ADP-ribose) polymerase (PARP) inhibition could render SCLC more susceptible to immune checkpoint blockade, and this trial enrolled relapsed SclC patients who received durvalumab 1500 mg q 4 weeks and olaparib 300 mg BID.

Pembrolizumab in lung cancer: current evidence and future perspectives.

The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrology.
...

References

SHOWING 1-10 OF 34 REFERENCES

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy.

Pembrolizumab for the treatment of non-small cell lung cancer

Pembrolizumab, demonstrated durable response and prolonged OS especially in NSCLC patients with high expression of PD-1, thereby suggests a new treatment paradigm.

Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.

The PD-L1 immunohistochemical assay shows the potential for enrichment of trial populations and as a companion diagnostic tool in non-small cell lung cancer.

Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.

3009 Background: Pembrolizumab is a potent, highly selective, humanized monoclonal antibody against PD-1 that has shown robust antitumor activity against several advanced malignancies. In phase 1

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.